Xtandi seeks first-line status

Share this article:

The FDA gave Medivation and Astellas a boost by giving priority review to the partners' application to expand the prostate cancer drug's indication to include first-line status.

The drug is currently indicated for metastatic castration-resistant prostate cancer patients who have previously undergone chemotherapy and was approved in 2012.

PM Live notes that a pre-chemo indication will allow Medivation to provide early treatment competition for Janssen's prostate cancer drug Zytiga, which lassoed the pre-chemo approval in July 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.